NMD Pharma, Aarhus, Denmark, July 23, 2026
NMD Pharma has announced the publication of groundbreaking clinical and preclinical research in The Journal of Clinical Investigation identifying neuromuscular junction (NMJ) transmission failure as a previously underrecognized and potentially reversible contributor to age-related muscle weakness and sarcopenia. The collaborative study, led by researchers from the University of Missouri and international neuromuscular experts, demonstrated that older adults with clinically significant muscle weakness exhibit impaired NMJ transmission, with the severity of transmission failure closely correlating with the degree of muscle weakness. The findings also showed that small-molecule inhibition of the skeletal muscle-specific ClC-1 ion channel restored muscle excitability, improved NMJ transmission, and enhanced muscle function in aged animal models. These results provide strong scientific support for ClC-1 inhibition as a promising therapeutic strategy for treating sarcopenia while reinforcing NMD Pharma’s long-term focus on restoring skeletal muscle function through its proprietary ClC-1 platform.
Research Identifies a Reversible Driver of Sarcopenia
The newly published study provides compelling evidence that age-related muscle weakness is not solely caused by declining nerve signals but also by the muscle’s reduced ability to respond effectively to those signals. Researchers found that NMJ transmission failure represents an important postsynaptic mechanism contributing to sarcopenia, opening a new therapeutic avenue for intervention. In preclinical studies, inhibition of the ClC-1 ion channel significantly improved neuromuscular communication and muscle performance in aged rodent models displaying deficits similar to those observed in older adults with muscle weakness. According to study lead Dr. W. David Arnold, restoring muscle responsiveness through ClC-1 modulation may help address one of the underlying biological drivers of declining physical function. The publication establishes a strong mechanistic rationale for targeting ClC-1 to improve muscle strength, mobility, and overall functional capacity in aging populations.
NMD Pharma Expands ClC-1 Platform Beyond Rare Neuromuscular Diseases
The findings further strengthen NMD Pharma’s strategy of developing first-in-class ClC-1 modulators for both rare neuromuscular disorders and more prevalent skeletal muscle diseases. The company’s lead investigational therapy, ignaseclant, is already being evaluated across multiple rare neuromuscular indications and serves as the clinical foundation for the broader ClC-1 development platform. Building on this experience, NMD Pharma is advancing next-generation programs aimed at treating moderate-to-severe sarcopenia, a condition affecting millions of older adults worldwide. According to Chief Executive Officer Thomas Holm Pedersen, restoring reliable skeletal muscle activation has the potential to improve muscle strength, physical performance, independence, and quality of life while supporting healthier aging through improved skeletal muscle function. The company’s integrated research capabilities in skeletal muscle biology, ion channel pharmacology, electrophysiology, medicinal chemistry, and translational science continue to drive innovation across its expanding pipeline.
Advertisement
Clinical Development Continues Across Multiple Muscle Disorders
Alongside the publication, NMD Pharma highlighted continued progress across its clinical development portfolio. Earlier this year, the company reported positive Phase 2a SYNAPSE-CMT topline results demonstrating meaningful improvements in muscle strength, motor performance, and patient-reported outcomes in individuals with Charcot-Marie-Tooth disease treated with ignaseclant. The company has also completed a Phase 1b/2a trial evaluating the therapy in adults with spinal muscular atrophy (SMA), with topline data expected during the second half of 2026. Additionally, results from an ongoing Phase 2b study in generalized myasthenia gravis (gMG) involving patients with AChR and MuSK autoantibodies are anticipated in the first quarter of 2027. Together with the newly published sarcopenia research, these programs reinforce the potential of NMD Pharma’s ClC-1 inhibition platform to address a broad spectrum of diseases characterized by impaired skeletal muscle activation and progressive muscle weakness.
Source: NMD Pharma press release
